Bruce Keith

756 total citations
15 papers, 504 citations indexed

About

Bruce Keith is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Bruce Keith has authored 15 papers receiving a total of 504 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 5 papers in Pulmonary and Respiratory Medicine and 3 papers in Molecular Biology. Recurrent topics in Bruce Keith's work include Colorectal Cancer Treatments and Studies (7 papers), Cancer Treatment and Pharmacology (5 papers) and Pancreatic and Hepatic Oncology Research (3 papers). Bruce Keith is often cited by papers focused on Colorectal Cancer Treatments and Studies (7 papers), Cancer Treatment and Pharmacology (5 papers) and Pancreatic and Hepatic Oncology Research (3 papers). Bruce Keith collaborates with scholars based in United States, Canada and Australia. Bruce Keith's co-authors include Jean L. Grem, Yong‐Jiang Xu, Susan Ellard, Christian Kollmannsberger, Bernhard J. Eigl, Muhammad Zulfiqar, Alexander W. Wyatt, Joanna Vergidis, Sinja Taavitsainen and Katherine Sunderland and has published in prestigious journals such as Journal of Clinical Oncology, The Lancet Oncology and BMC Cancer.

In The Last Decade

Bruce Keith

15 papers receiving 492 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Bruce Keith United States 10 262 243 121 105 86 15 504
Alan D. Smith United Kingdom 14 361 1.4× 236 1.0× 234 1.9× 171 1.6× 68 0.8× 35 635
Florence Lefresne France 13 299 1.1× 186 0.8× 54 0.4× 118 1.1× 85 1.0× 26 491
P. Stattin Sweden 7 257 1.0× 184 0.8× 186 1.5× 160 1.5× 30 0.3× 17 512
Toshiaki Shinojima Japan 15 290 1.1× 196 0.8× 273 2.3× 180 1.7× 32 0.4× 46 664
Ione Tamagnini Italy 13 249 1.0× 325 1.3× 269 2.2× 141 1.3× 51 0.6× 24 720
Hiroshi Hongo Japan 13 274 1.0× 119 0.5× 169 1.4× 108 1.0× 51 0.6× 74 511
Hiroshi Wakui Japan 15 345 1.3× 412 1.7× 233 1.9× 74 0.7× 39 0.5× 42 816
John Frye United States 10 172 0.7× 286 1.2× 222 1.8× 91 0.9× 30 0.3× 24 754
Thomas Spires United States 12 268 1.0× 182 0.7× 170 1.4× 47 0.4× 37 0.4× 15 790
Teresa Parli United States 9 279 1.1× 96 0.4× 73 0.6× 97 0.9× 125 1.5× 20 393

Countries citing papers authored by Bruce Keith

Since Specialization
Citations

This map shows the geographic impact of Bruce Keith's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bruce Keith with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bruce Keith more than expected).

Fields of papers citing papers by Bruce Keith

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bruce Keith. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bruce Keith. The network helps show where Bruce Keith may publish in the future.

Co-authorship network of co-authors of Bruce Keith

This figure shows the co-authorship network connecting the top 25 collaborators of Bruce Keith. A scholar is included among the top collaborators of Bruce Keith based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bruce Keith. Bruce Keith is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Khalaf, Daniel, Matti Annala, Sinja Taavitsainen, et al.. (2019). Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial. The Lancet Oncology. 20(12). 1730–1739. 213 indexed citations
2.
Khalaf, Daniel, Arun Azad, Katherine Sunderland, et al.. (2017). A prognostic model for stratifying clinical outcomes in chemotherapy-naive metastatic castration-resistant prostate cancer patients treated with abiraterone acetate. Canadian Urological Association Journal. 12(2). E47–52. 10 indexed citations
3.
Morris, Donald G., Dongsheng Tu, Mustapha Tehfé, et al.. (2016). A Randomized Phase II study of Reolysin in Patients with Previously Treated Advanced or Metatstatic Non Small Cell Lung Cancer (NSCLC) receiving Standard Salvage Chemotherapy – Canadian Cancer Trials Group IND 211.. Journal of Clinical Oncology. 34(15_suppl). e20512–e20512. 5 indexed citations
4.
Keith, Bruce. (2008). Systematic review of the clinical effect of glucocorticoids on nonhematologic malignancy. BMC Cancer. 8(1). 84–84. 84 indexed citations
5.
Xu, Yan, Bruce Keith, & Jean L. Grem. (2004). Measurement of the anticancer agent gemcitabine and its deaminated metabolite at low concentrations in human plasma by liquid chromatography-mass spectrometry. Journal of Chromatography B. 802(2). 263–270. 31 indexed citations
6.
Keith, Bruce, Yong‐Jiang Xu, & Jean L. Grem. (2003). Measurement of the anti-cancer agent gemcitabine in human plasma by high-performance liquid chromatography. Journal of Chromatography B. 785(1). 65–72. 35 indexed citations
7.
Grem, Jean L., Mary Quinn, Bruce Keith, et al.. (2003). A phase I and pharmacologic study of weekly gemcitabine in combination with infusional 5-fluorodeoxyuridine and oral calcium leucovorin. Cancer Chemotherapy and Pharmacology. 52(6). 487–496. 4 indexed citations
8.
Keith, Bruce, Suzanne Zentko, Nancy Harold, et al.. (2002). Impact of two weekly schedules of oral eniluracil given with fluorouracil and leucovorin on the duration of dihydropyrimidine dehydrogenase inhibition.. PubMed. 8(5). 1045–50. 4 indexed citations
9.
Keith, Bruce, Mark Vincent, Larry Stitt, et al.. (2002). Subsets More Likely to Benefit From Surgery or Prophylactic Cranial Irradiation After Chemoradiation for Localized Non–Small-Cell Lung Cancer. American Journal of Clinical Oncology. 25(6). 583–587. 23 indexed citations
10.
Grem, Jean L., Nancy Harold, Bruce Keith, et al.. (2002). A phase I pharmacologic and pharmacodynamic study of pyrazoloacridine given as a weekly 24-hour continuous intravenous infusion in adult cancer patients.. PubMed. 8(7). 2149–56. 7 indexed citations
11.
Saif, Muhammad Wasif, et al.. (2001). Peripheral neuropathy associated with weekly oral 5-fluorouracil, leucovorin and eniluracil. Anti-Cancer Drugs. 12(6). 525–531. 30 indexed citations
12.
Keith, Bruce & Vivien Bramwell. (2000). Pyomyositis After Chemotherapy for Breast Cancer. American Journal of Clinical Oncology. 23(1). 42–44. 9 indexed citations
13.
Tomiak, Anna, Mark Vincent, Walter Kocha, et al.. (2000). Standard Dose (Mayo Regimen) 5-Fluorouracil and Low Dose Folinic Acid: Prohibitive Toxicity?. American Journal of Clinical Oncology. 23(1). 94–98. 27 indexed citations
14.
Keith, Bruce. (2000). Ursodeoxycholic acid to inhibit the growth of hepatic metastases. Medical Hypotheses. 55(5). 379–382. 2 indexed citations
15.
Grem, Jean L., Nancy Harold, Jeremy Shapiro, et al.. (2000). Phase I and Pharmacokinetic Trial of Weekly Oral Fluorouracil Given With Eniluracil and Low-Dose Leucovorin to Patients With Solid Tumors. Journal of Clinical Oncology. 18(23). 3952–3963. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026